Manchester Centre for Nuclear Hormone Research in Disease

Researchers and doctors from the Biomedical Research Centre and The University of Manchester have joined forces with pharmaceutical company GlaxoSmithKline in this innovative, joined-up approach to tackling chronic inflammatory disease.

The Manchester Centre for Nuclear Hormone Research in Disease sees the NHS, academics and industry working together to find new therapies for inflammatory conditions such as asthma and rheumatoid arthritis.

Leading the research teams is Visiting Professor Stuart Farrow, newly appointed Chair in Experimental Therapeutics at the Biomedical Research Centre.  Professor Farrow will also continue his current role at GlaxoSmithKline, where he has been developing new medicines for lung diseases such as asthma since 2000.

The centre is jointly managed by Professors David Ray and Andrew Loudon, with Dr Roberto Solari of GlaxoSmithKline. 

It will focus on understanding the role of nuclear hormone receptors in inflammatory diseases and seeking to identify compounds that could help lead to new treatments.

For more information about the Manchester Centre for Nuclear Hormone Research in Disease, please contact: